Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Title: Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors Presenter: Brian A. Van Tine, M.D., Ph.D., Washington University in St. Louis Abstract ID#: 3102 Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Location: Hall A, McCormick Place, Chicago, Illinois — KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — SAN MATEO, Calif. and ...